Heparin Glycan Microarray for Screening
用于筛选的肝素聚糖微阵列
基本信息
- 批准号:7421026
- 负责人:
- 金额:$ 20万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-05-15 至 2010-04-30
- 项目状态:已结题
- 来源:
- 关键词:AnabolismAnticoagulantsAntithrombin IIIAreaBindingBiologicalBiologyBiopolymersCell CommunicationCellsChemistryClinicalCollectionCommunicationComplexConfidential InformationCytochrome P450DevelopmentDiagnosticDisciplineDrug EvaluationDrug InteractionsDrug toxicityEnzymesEscherichia coliGenomicsGlycosaminoglycansGoalsGolgi ApparatusHeparinHeparitin SulfateHumanLaboratoriesLeadLiquid substanceModificationNIH Program AnnouncementsNumbersOligosaccharidesOrganPatientsPharmaceutical PreparationsPharmacologic SubstancePhasePolysaccharidesProcessProteomicsRecombinantsResearchSamplingScienceScreening procedureSmall Business Technology Transfer ResearchSpecificitySpeedStructureStructure-Activity RelationshipTechnologyTissuesToxic effectTreatment ProtocolsUridine Diphosphate SugarsWritingbasecapsular polysaccharide K5cationic antimicrobial protein CAP 37commercial applicationdesigndrug developmentglycosyltransferasehigh throughput analysishuman RPL29 proteinmetabolomicsnew technologynext generationprogramsresponsesmall molecule
项目摘要
DESCRIPTION (provided by applicant): The proposed research program applies Solidus technology in microarraying, biocatalysis, and screening and the Linhardt group's expertise in heparin/heparan sulfate to the field of glycomics. Glycomics, the comprehensive study of glycan structure-function relationship, is a sub-discipline of metabolomics and the next step beyond genomics and proteomics. Heparin glycosaminoglycans (heparin and heparan sulfate) are among the most structural complex biopolymers. These glycans carry and store significant biological information crucial in virtually all pathological and pathophysiological processes involving cell-cell interaction and communication. The specific aims and milestones of this Phase I STTR proposal are to: 1. prepare a heparin glycan microarray; 2. probe this microarray with the highly specific heparin-binding protein, antithrombin III; 3. prepare an enzyme-modified heparosan microarray; 4. probe this microarray with a collection of heparin-binding proteins to examine binding specificity; and 5. prepare a structurally defined glycan microarray based on the glycosyltransferase extension, and enzymatic modification of heparosan oligosaccharide acceptors for probing with heparin-binding proteins. Phase I will focus on developing the core technology required for developing a HepGly chip as a glycomics platform for screening interactions with heparin-binding proteins. Potential applications for a HepGly microarray include the development of the next generation of heparin-based drugs, the evaluation small molecule drugs that antagonize with heparin/heparan sulfate interaction with heparin-binding proteins and the rapid screening of biological samples in diagnostic applications. A phase II proposal will be prepared to develop these commercial applications.
描述(由申请人提供):拟议的研究计划将 Solidus 技术应用于微阵列、生物催化和筛选,并将 Linhardt 小组在肝素/硫酸乙酰肝素方面的专业知识应用于糖组学领域。糖组学是对聚糖结构与功能关系的综合研究,是代谢组学的一个子学科,是基因组学和蛋白质组学的下一步。肝素糖胺聚糖(肝素和硫酸乙酰肝素)是结构最复杂的生物聚合物之一。这些聚糖携带并存储在涉及细胞间相互作用和通讯的几乎所有病理和病理生理过程中至关重要的重要生物信息。第一阶段 STTR 提案的具体目标和里程碑是: 1. 制备肝素聚糖微阵列; 2. 用高度特异性的肝素结合蛋白抗凝血酶 III 探测该微阵列; 3.制备酶修饰的heparosan微阵列; 4. 用一组肝素结合蛋白探测该微阵列以检查结合特异性; 5.基于糖基转移酶延伸和肝素寡糖受体的酶促修饰制备结构明确的聚糖微阵列,用于用肝素结合蛋白进行探测。第一阶段将重点开发开发 HepGly 芯片所需的核心技术,作为筛选与肝素结合蛋白相互作用的糖组学平台。 HepGly 微阵列的潜在应用包括开发下一代基于肝素的药物、评估拮抗肝素/硫酸乙酰肝素与肝素结合蛋白相互作用的小分子药物以及诊断应用中生物样品的快速筛选。将准备第二阶段提案来开发这些商业应用。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Glycomics approaches for the bioassay and structural analysis of heparin/heparan sulphates.
用于肝素/硫酸乙酰肝素生物测定和结构分析的糖组学方法。
- DOI:10.3390/metabo2041060
- 发表时间:2012
- 期刊:
- 影响因子:4.1
- 作者:Puvirajesinghe,TaniaM;Turnbull,JeremyE
- 通讯作者:Turnbull,JeremyE
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERT J LINHARDT其他文献
ROBERT J LINHARDT的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERT J LINHARDT', 18)}}的其他基金
Heparan Sulfate 3-O-Sulfation in Transcellular Propagation of Tauopathy in Alzheimer's Disease
硫酸乙酰肝素 3-O-硫酸化在阿尔茨海默氏病 Tau 蛋白病跨细胞传播中的作用
- 批准号:
10054740 - 财政年份:2020
- 资助金额:
$ 20万 - 项目类别:
Endothelial glycocalyx reconstitution during sepsis
脓毒症期间的内皮糖萼重建
- 批准号:
8803172 - 财政年份:2014
- 资助金额:
$ 20万 - 项目类别:
Endothelial glycocalyx reconstitution during sepsis
脓毒症期间的内皮糖萼重建
- 批准号:
9278256 - 财政年份:2014
- 资助金额:
$ 20万 - 项目类别:
Endothelial glycocalyx reconstitution during sepsis
脓毒症期间的内皮糖萼重建
- 批准号:
8927683 - 财政年份:2014
- 资助金额:
$ 20万 - 项目类别:
Endothelial glycocalyx reconstitution during sepsis
脓毒症期间的内皮糖萼重建
- 批准号:
9066215 - 财政年份:2014
- 资助金额:
$ 20万 - 项目类别:
Characterization of Anticoagulant Heparin and Related Polysaccharides
抗凝肝素及相关多糖的表征
- 批准号:
7939713 - 财政年份:2009
- 资助金额:
$ 20万 - 项目类别:
Characterization of Anticoagulant Heparin and Related Polysaccharides
抗凝肝素及相关多糖的表征
- 批准号:
7853484 - 财政年份:2009
- 资助金额:
$ 20万 - 项目类别:
Stable Carbohydrate Libraries in Infectious Disease
传染病中的稳定碳水化合物库
- 批准号:
7748958 - 财政年份:2007
- 资助金额:
$ 20万 - 项目类别:
相似海外基金
EPIphANy (Evaluation of Pharmacological Interactions with Anticoagulants in caNcer patients) program - prostate cancer cohort
EPIPHANy(癌症患者抗凝药理相互作用的评估)计划 - 前列腺癌队列
- 批准号:
479295 - 财政年份:2023
- 资助金额:
$ 20万 - 项目类别:
Operating Grants
Inhibitors of Human Factor XIIIa as New Anticoagulants
人类因子 XIIIa 抑制剂作为新型抗凝剂
- 批准号:
10629057 - 财政年份:2023
- 资助金额:
$ 20万 - 项目类别:
Establishment of comprehensive monitoring of direct oral anticoagulants (DOACs) for clinical application
建立临床应用直接口服抗凝剂(DOAC)综合监测体系
- 批准号:
23K06906 - 财政年份:2023
- 资助金额:
$ 20万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Interactions of Enzyme-Inducing Antiepileptic Drugs with Direct-Acting Oral Anticoagulants: Risk of Thromboembolic Events
酶诱导抗癫痫药物与直接作用口服抗凝剂的相互作用:血栓栓塞事件的风险
- 批准号:
10605482 - 财政年份:2023
- 资助金额:
$ 20万 - 项目类别:
The Comparative Effectiveness and Safety of Oral Anticoagulants in Patients with Cirrhosis and Atrial Fibrillation
口服抗凝药对肝硬化合并心房颤动患者的有效性和安全性比较
- 批准号:
10559071 - 财政年份:2023
- 资助金额:
$ 20万 - 项目类别:
Search for indicators of blood levels of directly inhibitory oral anticoagulants in coagulation tests using artificial intelligence
使用人工智能在凝血测试中搜索直接抑制性口服抗凝剂的血液水平指标
- 批准号:
22K07388 - 财政年份:2022
- 资助金额:
$ 20万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Bleeding on Direct Oral Anticoagulants: Identification of Genetic Risk Factors and a Polygenic Predictive Score in Patients with Atrial Fibrillation
直接口服抗凝剂导致的出血:房颤患者遗传风险因素的鉴定和多基因预测评分
- 批准号:
10536789 - 财政年份:2022
- 资助金额:
$ 20万 - 项目类别:
Study on proper use of oral anticoagulants combined with 5-fluorouracil
口服抗凝药联合5-氟尿嘧啶正确使用研究
- 批准号:
22K06743 - 财政年份:2022
- 资助金额:
$ 20万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Benchmarking a point-of-care test kit for detection of direct-oral anticoagulants
用于检测直接口服抗凝剂的即时检测试剂盒的基准测试
- 批准号:
461790 - 财政年份:2022
- 资助金额:
$ 20万 - 项目类别:
Operating Grants
Direct oral anticoagulants and the risk of colorectal and pancreatic cancers: a population-based cohort study.
直接口服抗凝剂与结直肠癌和胰腺癌的风险:一项基于人群的队列研究。
- 批准号:
474475 - 财政年份:2022
- 资助金额:
$ 20万 - 项目类别:
Studentship Programs














{{item.name}}会员




